Double maintains 3 strategies that include APLS - Apellis Pharmaceuticals, Inc.
Current Value
$17.421 Year Return
Current Value
$17.421 Year Return
Yahoo
Apellis Pharmaceuticals Inc. (NASDAQ:APLS) is one of the most promising stocks according to Wall Street analysts. On July 1, Apellis Pharmaceuticals announced a capped royalty purchase agreement with Sobi. Under this agreement, Apellis will receive up to $300 million in exchange for 90% of its future ex-US royalties for Aspaveli (systemic pegcetacoplan). This non-dilutive financing […]
Yahoo
As the U.S. stock market navigates through a period of heightened volatility with the S&P 500 and Nasdaq Composite recently hitting record highs, investors are closely monitoring developments around tariffs and political shifts that could impact economic conditions. In this dynamic environment, identifying high-growth tech stocks requires careful consideration of their resilience to market fluctuations and adaptability to evolving global trade policies.
Yahoo
Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) is one of the 13 Best Pharma Stocks to Buy According to Wall Street Analysts. On July 1, analyst Judah Frommer from Morgan Stanley raised the firm’s price target on Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) to $26.00 from $25.00 while maintaining a Hold rating on the stock. Frommer attributed the rating to […]
Yahoo
Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) is among the best growth stocks to invest in for the next 5 years. The General Counsel of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS), David O. Watson, sold 5,000 shares of common stock for $18.77, higher than the current trading price of $17.62. This transaction, worth $93,850, although it follows a challenging period, […]
Yahoo
Sobi® (STO: SOBI), today announced a capped royalty purchase agreement with Apellis Pharmaceuticals, Inc. under which Sobi will reduce its ex-US royalty obligations to Apellis by 90% for Aspaveli® (systemic pegcetacoplan) in exchange for $275 million upfront and up to $25 million in additional milestone payments dependent on regulatory approvals in the European Union for C3 glomerulopathy (C3G) and primary immune complex membranoproliferative glomerulonephritis (IC-MPGN).
Yahoo
Apellis to receive $275 million upfront and up to $25 million in milestone payments upon EMA approval in C3G and IC-MPGNNon-dilutive financing further strengthens Apellis’ balance sheet Apellis retains full U.S. commercialization rights for systemic pegcetacoplanTransaction underscores shared confidence in the meaningful growth potential in rare kidney diseases WALTHAM, Mass., July 01, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced a capped royalty purchase
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| ROIV | 47.78% | $7.38B | +0.28% | 0.00% |
| ARWR | 45.21% | $2.42B | -30.81% | 0.00% |
| KYMR | 45.05% | $3.05B | +10.12% | 0.00% |
| DNLI | 44.70% | $2.08B | -31.63% | 0.00% |
| IMVT | 44.44% | $2.89B | -43.13% | 0.00% |
| DAWN | 44.35% | $670.00M | -55.55% | 0.00% |
| RARE | 43.66% | $3.73B | -6.70% | 0.00% |
| EYPT | 43.57% | $684.68M | +13.46% | 0.00% |
| BPMC | 43.54% | $8.30B | +11.41% | 0.00% |
| BEAM | 42.79% | $2.04B | -14.85% | 0.00% |
| CRNX | 41.86% | $2.75B | -39.10% | 0.00% |
| CLDX | 41.58% | $1.42B | -42.61% | 0.00% |
| NTLA | 41.47% | $1.15B | -50.04% | 0.00% |
| IDYA | 41.40% | $1.88B | -44.46% | 0.00% |
| CYTK | 41.33% | $4.09B | -37.57% | 0.00% |
| XNCR | 40.65% | $588.58M | -55.05% | 0.00% |
| OCUL | 40.37% | $1.58B | +53.80% | 0.00% |
| VTYX | 40.01% | $148.02M | -11.11% | 0.00% |
| RGNX | 39.92% | $440.40M | -17.47% | 0.00% |
| ELVN | 39.85% | $1.18B | -13.35% | 0.00% |
| Name | Correlation | AUM | Expense Ratio |
|---|---|---|---|
| IBTJ | -0.15% | $682.49M | 0.07% |
| STOT | -0.17% | $252.89M | 0.45% |
| GOVT | -0.18% | $27.33B | 0.05% |
| SPTI | 0.18% | $8.73B | 0.03% |
| IBTK | 0.23% | $446.70M | 0.07% |
| STIP | 0.25% | $12.67B | 0.03% |
| CTA | 0.35% | $1.06B | 0.76% |
| IBTM | 0.35% | $315.31M | 0.07% |
| USO | 0.38% | $1.17B | 0.6% |
| BNO | -0.40% | $107.02M | 1% |
| JMST | 0.43% | $4.08B | 0.18% |
| UGA | 0.46% | $73.97M | 0.97% |
| WEAT | 0.48% | $124.20M | 0.28% |
| IBTI | -0.53% | $1.06B | 0.07% |
| VGIT | 0.54% | $31.66B | 0.04% |
| KCCA | -0.57% | $108.82M | 0.87% |
| SHV | 0.58% | $20.55B | 0.15% |
| DBE | -0.72% | $53.48M | 0.77% |
| CORN | -0.75% | $45.73M | 0.2% |
| USL | 0.75% | $43.09M | 0.85% |
| Name | Correlation | AUM | Expense Ratio |
|---|---|---|---|
| XBI | 57.01% | $4.90B | 0.35% |
| IBB | 52.68% | $5.44B | 0.45% |
| GNOM | 52.67% | $46.32M | 0.5% |
| PBE | 47.29% | $228.63M | 0.58% |
| ARKG | 46.21% | $1.06B | 0.75% |
| IWO | 44.27% | $11.87B | 0.24% |
| BBH | 44.23% | $340.09M | 0.35% |
| IWC | 43.91% | $847.74M | 0.6% |
| IWM | 43.69% | $66.85B | 0.19% |
| VTWO | 43.44% | $12.85B | 0.07% |
| PAWZ | 43.02% | $63.22M | 0.5% |
| KJUL | 43.00% | $153.16M | 0.79% |
| PINK | 42.57% | $130.93M | 0.5% |
| KJAN | 41.94% | $287.30M | 0.79% |
| SCHA | 41.65% | $17.76B | 0.04% |
| IWN | 41.35% | $11.45B | 0.24% |
| FBT | 40.98% | $1.02B | 0.54% |
| ESML | 40.90% | $1.90B | 0.17% |
| PRFZ | 40.80% | $2.43B | 0.34% |
| VBK | 40.79% | $19.31B | 0.07% |
| Name | Correlation | AUM | Expense Ratio |
|---|---|---|---|
| VIXY | -32.55% | $185.99M | 0.85% |
| BTAL | -30.93% | $312.42M | 1.43% |
| TAIL | -29.86% | $95.09M | 0.59% |
| ULST | -15.28% | $595.49M | 0.2% |
| CLIP | -15.05% | $1.54B | 0.07% |
| USDU | -14.56% | $124.09M | 0.5% |
| PSQA | -11.38% | $36.46M | 0.2% |
| XHLF | -11.11% | $1.73B | 0.03% |
| IVOL | -9.76% | $342.02M | 1.02% |
| XONE | -9.66% | $627.68M | 0.03% |
| LDUR | -9.22% | $922.21M | 0.5% |
| UUP | -8.51% | $198.33M | 0.77% |
| FTSD | -7.63% | $233.04M | 0.25% |
| SPTS | -6.96% | $5.77B | 0.03% |
| UTWO | -6.31% | $376.38M | 0.15% |
| BUXX | -6.19% | $312.37M | 0.25% |
| SHYM | -5.90% | $355.63M | 0.35% |
| IBTG | -5.57% | $1.92B | 0.07% |
| BILZ | -5.27% | $861.77M | 0.14% |
| GBIL | -5.25% | $6.35B | 0.12% |
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| PARAA | 0.04% | $15.51B | +8.80% | 0.87% |
| LMT | -0.20% | $108.48B | +0.59% | 2.80% |
| OCFT | -0.42% | $272.27M | +313.41% | 0.00% |
| BULL | 0.65% | $6.23B | +15.20% | 0.00% |
| CCEC | -0.73% | $1.02B | +3.91% | 2.56% |
| CIG.C | -0.77% | $2.65B | +23.47% | 0.00% |
| CHRW | 0.82% | $11.67B | +13.61% | 2.51% |
| COR | -0.90% | $57.77B | +34.02% | 0.72% |
| IMNN | 0.92% | $14.82M | -45.57% | 0.00% |
| VSTA | 0.92% | $332.04M | +38.00% | 0.00% |
| FROG | 0.96% | $4.79B | +17.51% | 0.00% |
| DFDV | 1.01% | $298.06M | +2,070.86% | 0.00% |
| UUU | 1.14% | $8.42M | +150.90% | 0.00% |
| T | 1.16% | $203.56B | +50.48% | 3.92% |
| STG | 1.22% | $31.09M | -22.74% | 0.00% |
| OXBR | 1.22% | $15.78M | -4.50% | 0.00% |
| CME | -1.23% | $99.33B | +45.14% | 1.75% |
| IMDX | 1.27% | $83.22M | -2.68% | 0.00% |
| ARLP | 1.36% | $3.42B | +8.34% | 10.50% |
| ANGI | 1.39% | $780.27M | -19.10% | 0.00% |
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| K | -11.29% | $27.53B | +40.77% | 2.87% |
| VSA | -9.92% | $8.76M | -15.57% | 0.00% |
| LITB | -9.84% | $23.17M | -74.54% | 0.00% |
| MO | -8.36% | $100.29B | +27.49% | 6.88% |
| CORT | -8.36% | $7.23B | +127.96% | 0.00% |
| HUSA | -7.47% | $18.72M | -18.25% | 0.00% |
| MCK | -7.40% | $90.44B | +23.40% | 0.39% |
| PULM | -6.26% | $23.96M | +218.45% | 0.00% |
| ED | -5.01% | $35.78B | +11.77% | 3.38% |
| RPRX | -4.79% | $14.96B | +38.55% | 2.41% |
| AEP | -4.10% | $55.53B | +18.55% | 3.53% |
| CBOE | -4.02% | $24.35B | +37.95% | 1.09% |
| NEUE | -3.51% | $60.98M | +32.62% | 0.00% |
| EXC | -3.36% | $43.41B | +24.89% | 3.62% |
| FATBB | -3.12% | $46.51M | -10.46% | 10.73% |
| CEG | -2.38% | $98.05B | +44.86% | 0.47% |
| KR | -2.00% | $46.11B | +34.48% | 1.84% |
| ZCMD | -1.70% | $30.81M | +2.52% | 0.00% |
| CYCN | -1.56% | $10.08M | +36.52% | 0.00% |
| PPC | -1.56% | $10.85B | +36.15% | 0.00% |
